Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413270 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MAPK1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL13873102 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MAPK1NPSR1TSHRTDP1 | |
| SCHEMBL10250879 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MAPK1SMN1; SMN2NPSR1RAB9A | |
| SCHEMBL13061265 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MAPK1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL4960188 | 0.79 | MAPT (0.72) | ALDH1A1MAPK1SMN1; SMN2NPSR1GLA | |
| SCHEMBL13061271 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MAPK1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL13873123 | 0.78 | POLB (0.60) | ALDH1A1MAPK1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL13873127 | 0.78 | ALDH1A1 (0.55) | ALDH1A1NPSR1TSHRLMNAKMT2A | |
| SCHEMBL13006873 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPK1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL389333 | 0.76 | NAMPT (0.46) | ALDH1A1MAPK1SMN1; SMN2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | ALDH1A1 385/4885MAPK1 4561/4885SMN1; SMN2 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.